Acute @entity583 associated with high dose intravenous immunoglobulin infusion for XXXX . A study of four cases.

@entity1 @entity64 @entity455 @entity101 @entity28 @entity731 @entity453 @entity583 @entity792 @entity715
OBJECTIVE: To report on four @entity1 with @entity792 who developed acute @entity583 ( @entity583 ) during or soon after treatment with high dose intravenous immunoglobulins (IVIG) and to determine the clinical profile of @entity1 prone to this complication. METHODS: The clinical history of the four @entity1 is reported with details concerning age, sex, indication for IVIG treatment, risk factors, timing of the @entity583 and outcome. The relevant medical literature has been reviewed. RESULTS: The @entity1 , three @entity1 and one @entity1 , aged 42-67, received IVIG treatment for different @entity792 . All had a history of @entity731 or previous risk factors such as @entity101 , @entity64 , hyperlipidaemia and @entity28 . Two of the @entity1 suffered a @entity583 after the first infusion of IVIG while the others-after the 5th and 15th pulses. @entity583 occurred during the infusion in two @entity1 and after a few days in the others. All the @entity1 recovered from the acute event. These observations are in concert with sporadic cases of IVIG related @entity715 reported in the medical literature. CONCLUSION: In @entity1 with vascular risk factors such as old age, @entity101 , history of @entity64 or @entity453 , the possibility of IVIG related @entity455 should be considered and IVIG prescribed with a cautious reweighted risk/benefit consideration.
